NF2 and neoplasm: Although a recent study reported that MM cells lacking merlin were more sensitive to the FAK inhibitor VS-4718 in vitro and in tumor xenograft models in vivo [55], a phase II clinical trial investigating the effect of the FAK inhibitor VS-6063 alone (NCT01870609) failed in showing any benefit due to lack of efficacy in patients (for other ongoing or planned trials with FAK inhibitors including VS-6063, see https://clinicaltrials.gov/ct2/home).